CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent...
CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities...
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted...
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted...